Foghorn gives up on sole wholly owned clinical asset after phase 1 leukemia failure

Foghorn Therapeutics has finally given up on its only wholly owned clinical-stage candidate after the troubled cancer drug came up short in a phase 1 study in patients with acute myeloid leukemia (AML).